Traci McCarty | Vice President, Investor Relations |
Jean-Jacques Bienaimé | Chairman and Chief Executive Officer |
Robert Baffi | President of Global Manufacturing and Technical Operations |
Jeff Ajer | Executive Vice President and Chief Commercial Officer |
Henry Fuchs | President, Worldwide Research and Development |
Brian Mueller | Executive Vice President, Chief Financial Officer |
Joseph Schwartz | SVB Leerink |
Salveen Richter | Goldman Sachs |
Cory Kasimov | JPMorgan |
Robyn Karnauskas | SunTrust Securities |
Matthew Harrison | Morgan Stanley |
Philip Nadeau | Cowen and Company |
Joshua Schimmer | Evercore ISI |
Geoff Meacham | Bank of America Merrill Lynch |
Akash Tewari | Wolfe Research |
Welcome to the BioMarin Second Quarter 2020 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Tracy.
Thank you, Laurie, and thank you, everyone, for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development.